甲状腺乳头状癌的高细胞变异型:文献回顾及病例报告

Q4 Medicine

Opuholi Golovy i Sei Pub Date : 2020-11-16 DOI:10.17650/2222-1468-2020-10-3-48-54

E. Borodavina, P. A. Isaev, F. S. Sevrukov, A. V. Sidorin, V. Polkin, A. A. Ilyin, N. V. Severskaya, T. A. Agababyan, S. A. Ivanov, A. Kaprin

{"title":"甲状腺乳头状癌的高细胞变异型:文献回顾及病例报告","authors":"E. Borodavina, P. A. Isaev, F. S. Sevrukov, A. V. Sidorin, V. Polkin, A. A. Ilyin, N. V. Severskaya, T. A. Agababyan, S. A. Ivanov, A. Kaprin","doi":"10.17650/2222-1468-2020-10-3-48-54","DOIUrl":null,"url":null,"abstract":"The tall-cell variant of papillary thyroid carcinoma is a rare malignancy characterized by an aggressive course, low relapse-free survival, early metastasis, and frequent development of radioiodine refractoriness. We report two cases of tall-cell papillary thyroid carcinoma in patients who had disease progression after combination treatment and started to receive lenvatinib. We observed partial and complete regression of metastases in response to lenvatinib. Our findings are consistent with the results of other studies assessing treatment efficacy for disseminated tall-cell papillary thyroid carcinoma.","PeriodicalId":36598,"journal":{"name":"Opuholi Golovy i Sei","volume":"10 1","pages":"48-54"},"PeriodicalIF":0.0000,"publicationDate":"2020-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Tall-cell variant of papillary thyroid carcinoma: literature review and case reports\",\"authors\":\"E. Borodavina, P. A. Isaev, F. S. Sevrukov, A. V. Sidorin, V. Polkin, A. A. Ilyin, N. V. Severskaya, T. A. Agababyan, S. A. Ivanov, A. Kaprin\",\"doi\":\"10.17650/2222-1468-2020-10-3-48-54\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The tall-cell variant of papillary thyroid carcinoma is a rare malignancy characterized by an aggressive course, low relapse-free survival, early metastasis, and frequent development of radioiodine refractoriness. We report two cases of tall-cell papillary thyroid carcinoma in patients who had disease progression after combination treatment and started to receive lenvatinib. We observed partial and complete regression of metastases in response to lenvatinib. Our findings are consistent with the results of other studies assessing treatment efficacy for disseminated tall-cell papillary thyroid carcinoma.\",\"PeriodicalId\":36598,\"journal\":{\"name\":\"Opuholi Golovy i Sei\",\"volume\":\"10 1\",\"pages\":\"48-54\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-11-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Opuholi Golovy i Sei\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17650/2222-1468-2020-10-3-48-54\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Opuholi Golovy i Sei","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17650/2222-1468-2020-10-3-48-54","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

甲状腺乳头状癌的高细胞变异是一种罕见的恶性肿瘤，其特点是病程积极，无复发生存率低，早期转移，并经常发生放射性碘难治性。我们报告两例高细胞乳头状甲状腺癌患者在联合治疗后疾病进展并开始接受lenvatinib。我们观察到lenvatinib对转移瘤的部分和完全消退。我们的发现与其他评估弥散性高细胞乳头状甲状腺癌治疗效果的研究结果一致。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Tall-cell variant of papillary thyroid carcinoma: literature review and case reports

The tall-cell variant of papillary thyroid carcinoma is a rare malignancy characterized by an aggressive course, low relapse-free survival, early metastasis, and frequent development of radioiodine refractoriness. We report two cases of tall-cell papillary thyroid carcinoma in patients who had disease progression after combination treatment and started to receive lenvatinib. We observed partial and complete regression of metastases in response to lenvatinib. Our findings are consistent with the results of other studies assessing treatment efficacy for disseminated tall-cell papillary thyroid carcinoma.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Opuholi Golovy i Sei Medicine-Otorhinolaryngology

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

8 weeks